1. Distinct immune-tumor interactions occur in circulation, primary, and metastatic lesions.
2. CTCs evade NK surveillance by hijacking the HLA-E:CD94-NKG2A immune checkpoint molecule pair.
3. Blockade of HLA-E:CD94-NKG2A prevents PDAC tumor metastasis via blood circulation.
The article is generally reliable and trustworthy, as it provides a detailed analysis of the transcriptomes of human pancreatic ductal adenocarcinoma CTCs, primary, and metastatic lesions at single-cell scale. The authors provide evidence for their claims through cell-interaction analysis and functional studies in vitro and in vivo, as well as mechanistic studies that indicate platelet-derived RGS18 promotes the expression of HLA-E through AKT-GSK3β-CREB signaling. Furthermore, accession numbers are provided for all data used in the study to ensure transparency and accuracy.
However, there are some potential biases that should be noted. For example, the authors do not explore any counterarguments or present both sides equally when discussing their findings; instead they focus solely on supporting their own claims without considering any other perspectives or evidence that may contradict them. Additionally, there is no discussion of possible risks associated with blocking HLA-E:CD94-NKG2A or disrupting its interaction with CTCs; this could be an important point to consider before implementing such a strategy clinically. Finally, there is no mention of any promotional content or partiality in the article; however it is important to note that these factors can influence how readers interpret research results and should be taken into account when evaluating an article's trustworthiness and reliability.